Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Reduce" from Analysts

Key Points

• Y-mAbs Therapeutics has received a consensus recommendation of "Reduce" from ten research firms, with two analysts issuing a sell recommendation and eight a hold recommendation.
• The average 12-month price target for Y-mAbs Therapeutics is $9.62, following recent downgrades from several brokerage firms.
• Despite a negative return on equity of 24.60%, the company reported revenue of $19.52 million for the last quarter, surpassing consensus estimates.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been assigned an average recommendation of "Reduce" from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $9.6222.

A number of research analysts recently commented on YMAB shares. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Cantor Fitzgerald set a $8.60 price target on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a research report on Tuesday, August 5th. Wedbush downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and set a $8.60 price objective for the company. in a research note on Tuesday, August 5th. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their price target for the company from $26.00 to $8.60 in a research note on Tuesday, August 5th. Finally, HC Wainwright reiterated a "neutral" rating and set a $8.60 price objective (down from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC raised its position in shares of Y-mAbs Therapeutics by 5.7% in the second quarter. Acorn Capital Advisors LLC now owns 3,418,995 shares of the company's stock valued at $15,420,000 after purchasing an additional 183,608 shares during the period. Northern Trust Corp raised its holdings in Y-mAbs Therapeutics by 6.5% during the 4th quarter. Northern Trust Corp now owns 359,223 shares of the company's stock valued at $2,813,000 after buying an additional 21,936 shares during the last quarter. Nantahala Capital Management LLC bought a new position in Y-mAbs Therapeutics in the 2nd quarter worth $1,587,000. Stonepine Capital Management LLC raised its holdings in Y-mAbs Therapeutics by 117.5% in the 2nd quarter. Stonepine Capital Management LLC now owns 285,300 shares of the company's stock worth $1,287,000 after purchasing an additional 154,140 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Y-mAbs Therapeutics by 58.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock worth $1,052,000 after buying an additional 87,830 shares during the period. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock remained flat at $8.61 during midday trading on Wednesday. The stock has a 50 day simple moving average of $7.27 and a 200 day simple moving average of $5.49. Y-mAbs Therapeutics has a 52 week low of $3.55 and a 52 week high of $16.11. The company has a market capitalization of $391.24 million, a P/E ratio of -17.22 and a beta of 0.54.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.20. The company had revenue of $19.52 million during the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. Sell-side analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.